Literature DB >> 9738588

Tumor-suppressor p53: implications for tumor development and prognosis.

D G Kirsch1, M B Kastan.   

Abstract

The p53 protein plays a central role in modulating cellular responses to cytotoxic stresses by contributing to both cell-cycle arrest and programmed cell death. Loss of p53 function during tumorigenesis can lead to inappropriate cell growth, increased cell survival, and genetic instability. p53 gene mutations occur in approximately half of all malignancies from a wide range of human tumors. In some tumor types, these p53 mutations are associated with poor prognosis and treatment failure. Based on these insights, new approaches are being developed to prevent, diagnose, and treat cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738588     DOI: 10.1200/JCO.1998.16.9.3158

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  48 in total

1.  Identification of partial loss of function p53 gene mutations utilizing a yeast-based functional assay.

Authors:  G K Kovvali; B Mehta; C B Epstein; S G Lutzker
Journal:  Nucleic Acids Res       Date:  2001-03-01       Impact factor: 16.971

2.  p53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia.

Authors:  Hala E Hamouda; Soha S Zakaria; Saber A Ismail; Mahmoud A Khedr; Wael W Mayah
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

Review 3.  Molecular markers of pancreatic cancer: development and clinical relevance.

Authors:  Lucia C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Langenbecks Arch Surg       Date:  2008-02-12       Impact factor: 3.445

Review 4.  Cytogenetic, molecular genetic, and clinical characteristics of acute myeloid leukemia with a complex karyotype.

Authors:  Krzysztof Mrózek
Journal:  Semin Oncol       Date:  2008-08       Impact factor: 4.929

5.  mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status.

Authors:  Charles B Simone; Molykutty John-Aryankalayil; Sanjeewani T Palayoor; Adeola Y Makinde; David Cerna; Michael T Falduto; Scott R Magnuson; C Norman Coleman
Journal:  Transl Oncol       Date:  2013-10-01       Impact factor: 4.243

Review 6.  Genes that regulate metastasis and angiogenesis.

Authors:  C P Webb; G F Vande Woude
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

7.  Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.

Authors:  Fan Niu; Jin Yan; Bohan Ma; Shichao Li; Yongping Shao; Pengcheng He; Wanggang Zhang; Wangxiao He; Peter X Ma; Wuyuan Lu
Journal:  Biomaterials       Date:  2018-03-14       Impact factor: 12.479

8.  p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.

Authors:  T Megha; F Ferrari; A Benvenuto; C Bellan; A V Lalinga; S Lazzi; S Bartolommei; G Cevenini; L Leoncini; P Tosi
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

9.  Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy.

Authors:  Mart A A M Heesters; Jan Koudstaal; K Gwan Go; Willemina M Molenaar
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 10.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.